RGNX — REGENXBIO Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1590877 ·
Last close
$13.95
Market Cap
$721.18M
52W High
$15.88
52W Low
$5.45
ADV30
2,419,997
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 6,393,000 | -4,681,000 | -83,362,000 | -90,051,000 | 341,894,000 | 15,229,000 | 320,812,000 |
| Dec 2025 | 30,337,000 | 24,409,000 | -57,636,000 | -67,149,000 | 453,032,000 | 34,466,000 | 350,299,000 |
| Sep 2025 | 29,733,000 | 24,008,000 | -52,411,000 | -61,941,000 | 525,203,000 | 58,802,000 | 363,751,000 |
| Jun 2025 | 21,359,000 | 16,150,000 | -63,278,000 | -70,871,000 | 581,027,000 | 79,558,000 | 367,348,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-233,778,000
Investing CF
$9,977,000
Financing CF
$108,926,000
CapEx
$-2,625,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.60
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,216,078,000
Inventory
—
Receivables
$10,940,000
ST Investments
$135,262,000
EBIT TTM
$-244,866,000
Pretax Income TTM
$-290,012,000
Interest Exp TTM
$45,146,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$87,822,000
EBITDA
$-241,170,000
Free Cash Flow
$-138,978,624
Enterprise Value
$906,972,800
Total Cash
$150,491,008
Total Debt
$248,396,000
Shares Out
51,697,621
Trailing EPS
$-5.60
Book Value
$0.41
ROE
-196.4%
ROA
-38.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,441,000 | -161,198,000 | -193,878,000 | 453,032,000 | 350,299,000 | — | -123,963,000 |
| Dec 2024 | 83,328,000 | -231,245,000 | -227,102,000 | 465,989,000 | 206,338,000 | — | -173,125,000 |
| Dec 2023 | 90,242,000 | -268,128,000 | -263,494,000 | 573,970,000 | 262,228,000 | — | -218,407,000 |
| Dec 2022 | 112,724,000 | -262,876,000 | -280,321,000 | 833,268,000 | 317,073,000 | — | -207,488,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AURA | Aura Biosciences, Inc. | $707.51M | $6.84 | — |
| CADL | Candel Therapeutics, Inc. | $695.33M | $9.49 | — |
| ALLO | Allogene Therapeutics, Inc. | $690.31M | $2.00 | — |
| PRME | Prime Medicine, Inc. | $682.73M | $3.78 | — |
| ODTX | Odyssey Therapeutics, Inc. | $801.64M | $16.69 | — |
News headlines (Yahoo Finance, 1h cache)
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
2026-06-29 11:05 · Yahoo
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
2026-06-24 11:05 · Yahoo
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
2026-06-23 14:46 · Yahoo
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
2026-06-23 14:26 · Yahoo
Sector Update: Healthcare Stocks Rise Late Afternoon
2026-06-22 19:43 · Yahoo
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
2026-06-22 15:12 · Yahoo
RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome Therapy
2026-06-22 12:44 · Yahoo
Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection
2026-06-22 11:39 · Yahoo
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
2026-06-22 11:30 · Yahoo
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
2026-06-18 15:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.